Idiopathic Pulmonary Fibrosis

January 30, 2017January 30, 2017

‘Mini Lungs’ May Help Determine Which Therapies Best Suit Patients with IPF

“Mini lungs” created from the tissue of idiopathic pulmonary fibrosis (IPF) patients could be used to predict which of two medications would effectively treat them, according to a new study. The lung ... Read more

December 9, 2016December 9, 2016

Specific Cells Seen to Play Key Role in IPF Flares, Causing Multiple Organ Injury

Idiopathic Pulmonary Fibrosis

A new study suggests that an acute exacerbation — the sudden worsening of respiratory symptoms — in idiopathic pulmonary fibrosis (IPF) may actually be a systemic circulatory disorder resulting in multiple ... Read more

December 1, 2016December 1, 2016

First Patient Enrolled in Phase 2 Trial of Therapy for Hypoxemia in IPF

Idiopathic Pulmonary Fibrosis, News

Global Blood Therapeutics (GBT) recently announced it has enrolled the first patient into its Phase 2 ZEPHYR clinical trial (NCT02846324), assessing the safety and effectiveness of GBT440 in treating hypoxemia in ... Read more

October 25, 2016October 25, 2016

Phase 3 Trial Data Supports Effectiveness of Ofev in Treating IPF, Regardless of Disease Severity

Idiopathic Pulmonary Fibrosis, News

Analyses of data from two Phase 3 INPULSIS trials support using Ofev (nintedanib) for patients with idiopathic pulmonary fibrosis (IPF). The trials included IPF patients at different disease stages, and revealed that Ofev treatment is ... Read more

September 27, 2016September 27, 2016

UCLA Researchers Develop 3D ‘Lung Organoids’ as New Tool to Study Lung Diseases

Idiopathic Pulmonary Fibrosis, News

By converting adult lung cells to stem cells, a team of UCLA researchers developed mini-lungs in a culture dish, called lung organoids. This 3D lung tissue can be used to study ... Read more

September 22, 2016September 22, 2016

Researchers Identify Circulating Immune Cells as Potential IPF Biomarkers

Idiopathic Pulmonary Fibrosis, News

Researchers in Germany discovered that patients with idiopathic pulmonary fibrosis (IPF) have increased levels of myeloid-derived suppressor cells (MDSC) in the blood. The higher the number of MDSC, the more limited ... Read more

September 21, 2016September 21, 2016

New Data Supports Esbriet as Safe, Effective Treatment for IPF Patients

Idiopathic Pulmonary Fibrosis, News

Positive results from four analyses based on clinical trials developed by Roche to evaluate the effectiveness of Esbriet (pirfenidone), an oral antifibrotic medication approved by the U.S. Food and Drug ... Read more

September 14, 2016September 14, 2016

Boehringer Reports Long-term Positive Effects of IPF Therapy Ofev

Idiopathic Pulmonary Fibrosis, News

Boehringer Ingelheim recently shared positive data from a clinical trial evaluating long-term treatment with Ofev (nintedanib) in idiopathic pulmonary fibrosis (IPF) patients. The interim findings from the INPULSIS-ON extension trial were ... Read more

September 1, 2016September 1, 2016

Debate on Stem Cell Therapy for Pulmonary Fibrosis Heats Up as FDA Hearings Near

COPD, Idiopathic Pulmonary Fibrosis, News

As the U.S. Food and Drug Administration (FDA) readies a public hearing on stem cell therapy regulation, an ongoing debate over the clinical application of stem cell therapy has been heating ... Read more

August 30, 2016August 30, 2016

Clinicians Debate Management, Diagnosis of Respiratory Illnesses in Middle East

Asthma, COPD, Idiopathic Pulmonary Fibrosis, News

Leading medical professionals of European, Middle Eastern and African countries gathered at Boehringer Ingelheim’s second regional respiratory forum, themed “Innovative Solutions to Help Millions,” in Dubai to debate the clinical practices of ... Read more